Hoshino et al. (29) established a predictive nomogram of recurrence in stage II CRC, with a C-index of 0.64, based only on the following clinical characteristics: sex, tumor depth, tumor location, CEA level, LVI, and number of lymph nodes examined. This evidence concerns the gene CEACAM5 and neoplasm.